[1]李天予,孟令秀,范胜男,等.不稳定型心绞痛患者血清TNFSF15，GDF11表达水平与PCI术后支架内再狭窄的相关性分析[J].现代检验医学杂志,2025,40(02):83-86.[doi:10.3969/j.issn.1671-7414.2025.02.015]
　LI Tianyu,MENG Lingxiu,FAN Shengnan,et al.Correlation Analysis of Serum TNFSF15, GDF11 Expression Levels and In-stent Restenosis after PCI in Patients with Unstable Angina Pectoris[J].Journal of Modern Laboratory Medicine,2025,40(02):83-86.[doi:10.3969/j.issn.1671-7414.2025.02.015]
点击复制

不稳定型心绞痛患者血清TNFSF15，GDF11表达水平与PCI术后支架内再狭窄的相关性分析()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年02期
页码:
83-86
栏目:
论著
出版日期:
2025-03-15

文章信息/Info

Title:
Correlation Analysis of Serum TNFSF15, GDF11 Expression Levels and In-stent Restenosis after PCI in Patients with Unstable Angina Pectoris
文章编号:
1671-7414（2025）02-083-04
作者:
李天予，孟令秀，范胜男，孙文阳
（秦皇岛市第二医院心血管内一科，河北秦皇岛 066600）
Author(s):
LI Tianyu，MENG Lingxiu，FAN Shengnan，SUN Wenyang
（Department of Cardiovascular 1，the Second Hospital of Qinhuangdao，Hebei Qinhuangdao 066600, China）
关键词:
不稳定型心绞痛; 经皮冠状动脉介入治疗; 支架内再狭窄; 肿瘤坏死因子超家族15; 生长分化因子11
分类号:
R541.4；R392.11
DOI:
10.3969/j.issn.1671-7414.2025.02.015
文献标志码:
A
摘要:
目的 探讨血清肿瘤坏死因子超家族15（TNFSF15）、生长分化因子11（GDF11）与不稳定型心绞痛（UAP）患者经皮冠状动脉介入治疗(PCI) 支架内再狭窄（ISR）的相关性。方法 选择秦皇岛市第二医院2020 年1 月1 日～ 2021年1 月1 日收治的行PCI 治疗的350 例UAP 患者作为观察对象，根据其是否发生ISR 分为非ISR 组（n=246）和ISR组（n=104）；ELISA 测定血清TNFSF15 和GDF11 的水平；ROC 曲线分析血清TNFSF15, GDF11 水平对UAP 患者PCI 术后ISR 的预测价值；多因素Logistic 回归分析影响UAP 患者PCI 术后发生ISR 的因素。结果 与非ISR 组比较，ISR 组血糖、吸烟史和LDL-C 水平升高（t/χ2=22.908，18.869，47.337），血清TNFSF15（16.97±1.51 pg/ml vs18.35±1.62pg/ml）, GDF11（157.72±16.13pg/ml vs 174.11±18.65 pg/ml）水平降低（t=7.429，7.811），差异具有统计学意义（均P ＜ 0.001）；血清TNFSF15, GDF11 单独及联合预测UAP 患者PCI 术后发生ISR 的AUC（95%CI）分别为0.764(0.716 ～ 0.808)，0.781(0.734 ～ 0.823) 和0.849(0.807 ～ 0.885)，二者联合预测高于单独预测（Z=4.365，3.257，均P ＜ 0.001）；多因素Logistic 回归分析血清TNFSF15, GDF11 水平是UAP 患者PCI 术后发生ISR 的保护因素（Waldχ2=11.000，36.321，均P ＜ 0.05）。结论 PCI 术后发生ISR 的UAP 患者血清TNFSF15，GDF11 水平降低，二者对UAP 患者PCI 术后发生ISR 具有很好的预测价值。
Abstract:
Objective To investigate the correlation between serum TNF super family 15 (TNFSF15)，growth differentiation factor 11 (GDF11) and in-stent restenosis (ISR) in patients with unstable angina pectoris (UAP) undergoing percutaneous coronary intervention(PCI). Methods A total of 350 UAP patients who underwent PCI treatment in the Second Hospital of Qinhuangdao from January 1, 2020 to January 1, 2021 were collected as observation subjects, and they were separated into non-ISR group (n=246) and ISR group (n=104) based on whether they had experienced ISR. ELISA was applied to determine the levels of serum TNFSF15 and GDF11, ROC curve was applied to analyze the predictive value of serum TNFSF15 and GDF11 levels for postoperative ISR in UAP patients after PCI, and multivariate Logistic regression was used to analyze the factors affecting the occurrence of ISR in UAP patients after PCI. Results Compared with the non-ISR group, the ISR group showed an increase in blood glucose, smoking history and LDL-C levels（t/ χ2=22.908，18.869，47.337），as well as elevated serum TNFSF15 levels (16.97 ± 1.51 pg/ml vs 18.35 ± 1.62pg/ml) and GDF11 levels (157.72 ± 16.13pg/ml vs 174.11 ± 18.65 pg/ml) decreased (t=7.429, 7.811), and the differences were statistically significant (all P<0.001). The AUC (95% CI) of serum TNFSF15 and GDF11 in dependently and jointly predicting ISR after PCI in UAP patients were 0.764 (0.716 ～ 0.808), 0.781 (0.734 ～ 0.823) and 0.849(0.807 ～ 0.885), respectively, and the joint prediction of the two was higher than the individual prediction (Z=4.365, 3.257, all P<0.001). Multivariate Logistic regression analysis of serum TNFSF15, the level of GDF11 was a protective factor for ISR in UAP patients after PCI (Wald χ2=11.000, 36.321, all P<0.05). Conclusion The serum levels of TNFSF15 and GDF11 decreased in UAP patients with postoperative ISR after PCI，which have good predictive value for the occurrence of ISR in UAP patients after PCI.

参考文献/References:

[1] BHATT D L, LOPES R D, HARRINGTON R A. Diagnosis and treatment of acute coronary syndromes: a review[J]. JAMA, 2022, 327(7): 662-675.
[2] ULLRICH H, OLSCHEWSKI M, M?NZEL T, et al. Coronary in-stent restenosis: predictors and treatment[J].Deutsches Arzteblatt International, 2021, 118(38): 637-644.
[3] 荣钰, 董莉. 血清MMP-9,TIMP-1 及VEGF 水平检测对冠状动脉支架内再狭窄诊断的研究进展[J]. 现代检验医学杂志,2021,36(1):161-164. RONG Yu, DONG Li. Research progress of serum MMP-9,TIMP-1 and VEGF levels in the diagnosis of intrastent restenosis[J]. Journal of Modern Laboratory Medicine, 2021, 36(1): 161-164.
[4] ZHAO Huanyu, ZHANG Qiangzhe. Signaling in TNFSF15-mediated suppression of VEGF production in endothelial cells[J]. Methods in Molecular Biology(Clifton, N.J.), 2021, 2248(1): 1-18.
[5] 王晓辉, 陈红男, 蒋锋, 等. 腔隙性脑梗死患者血清PECAM-1, GDF11, FGF21 与脑动脉血流动力学和颈动脉粥样硬化的关系[J]. 疑难病杂志,2023,22 (3):258-265. WANG Xiaohui, CHEN Hongnan, JIANG Feng, et al. Study on the relationship between serum PECAM-1, GDF11, FGF21 and cerebral artery hemodynamics and carotid atherosclerosis in patients with lacunar cerebral infarction [J]. Chinese Journal of Difficult and Complicated Cases, 2023, 22(3): 258-265.
[6] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 不稳定性心绞痛和非ST 段抬高心肌梗死诊断与治疗指南[J]. 中华心血管病杂志,2007,35(4): 295-304. Chinese Society of Cardiology,Editorial Board of Chinese Journal of Cardiology. Guideline for diagnosis and treatment of patients with unstable angina and non-ST-segment elevation myocardial infarction (no abstract) [J]. Chinese Journal of Cardiology, 2007, 35(4): 295-304.
[7] KAWAI K, VIRMANI R, FINN A V. In-stent restenosis[J].Interventional Cardiology Clinics, 2022, 11(4): 429-443.
[8] KRISTENSEN A M D, PAREEK M, KRAGHOLM K H, et al. Unstable angina as a component of primary composite endpoints in clinical cardiovascular trials: pros and cons[J]. Cardiology, 2022, 147(3): 235-247.
[9] OZAKI Y, HARA H, ONUMA Y, et al. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction(AMI) update 2022 [J]. Cardiovascular Intervention and Therapeutics, 2022, 37(1): 1-34.
[10] ALFONSO F, COUGHLAN J J, GIACOPPO D, et al. Management of in-stent restenosis[J]. EuroIntervention, 2022, 18(2): e103-e123.
[11] FURFARO F, ALFARONE L, GILARDI D, et al. TL1A: a new potential target in the treatment of inflammatory bowel disease[J]. Current Drug Targets, 2021, 22(7): 760-769.
[12] LI Jingzhou, SONG Fei, CHEN Ruolan, et al. Bradykininpretreated human cardiac-specific c-kit+ cells enhance exosomal miR-3059-5p and promote angiogenesis against hindlimb ischemia in mice[J]. Stem Cell Reviews and Reports, 2023, 19(7): 2481-2496.
[13] SOETISNA T W. CD133+ stem cell therapy effects on myocardial regeneration through increased vascular endothelial growth factor correlate with cardiac magnetic resonance imaging results in coronary artery bypass graft surgery patients with low ejection fraction[J]. Heart Surgery Forum, 2021,24(4): E670-E674.
[14] SUN Rui, HEDL M, ABRAHAM C. TNFSF15 promotes antimicrobial pathways in human macrophages and these are modulated by TNFSF15 disease-risk variants[J].Cellular and Molecular Gastroenterology and Hepatology, 2021, 11(1): 249-272.
[15] MACHELAK W, SZCZEPANIAK A, JACENIK D, et al. The role of GDF11 during inflammation - an overview [J]. Life Sciences, 2023, 322: 121650.
[16] LI Yuan, LI Yucong, LI Linlong, et al. The emerging translational potential of GDF11 in chronic wound healing [J]. Journal of Orthopaedic Translation, 2022, 34: 113-120.
[17] GORALTCHOUK A, MANKOVSKAYA S , KUZNETSOVA T, et al. Comparative evaluation of rhFGF18 and rhGDF11 treatment in a transient ischemia stroke model [J]. Restorative Neurology and Neuroscience, 2023, 41(5-6): 257-270.
[18] JIAO Lei, SHAO Yingchun, YU Qi, et al. GDF11 replenishment protects against hypoxia-mediated apoptosis in cardiomyocytes by regulating autophagy [J].European Journal of Pharmacology, 2020, 885: 173495.
[19] ZHAO Yun, ZHU Jinyun, ZHANG Ning, et al. GDF11 enhances therapeutic efficacy of mesenchymal stem cells for myocardial infarction via YME1L-mediated OPA1 processing[J]. Stem Cells Translational Medicine, 2020, 9(10): 1257-1271.
[20] LI Lei, GAO Yan, LIU Zhenchuan, et al. GDF11 alleviates neointimal hyperplasia in a rat model of artery injury by regulating endothelial NLRP3 inflammasome activation and rapid re-endothelialization[J]. Journal of Translational Medicine, 2022, 20(1): 28.

相似文献/References:

[1]刘亚东,齐　茗,王海晶,等.急性ST段抬高型心肌梗死患者Lp-PLA2基因多态性对PCI术后发生不良心脑血管事件的预测价值分析[J].现代检验医学杂志,2021,36(04):81.[doi:10.3969/j.issn.1671-7414.2021.04.017]
　LIU Ya-dong,QI Ming,WANG Hai-jing,et al.Analysis of the Predictive Value of Lp-PLA2 Gene Polymorphism in Patientswith Acute ST-Segment Elevation Myocardial Infarction for the Occurrenceof Adverse Cardiovascular and Cerebrovascular Events after PCI[J].Journal of Modern Laboratory Medicine,2021,36(02):81.[doi:10.3969/j.issn.1671-7414.2021.04.017]
[2]杨海燕,翁洁瑶,钱怡琳,等.急性ST段抬高型心肌梗死患者血清IRGM，Syndecan-1水平表达对PCI术后预后的影响[J].现代检验医学杂志,2025,40(03):123.[doi:10.3969/j.issn.1671-7414.2025.03.023]
　YANG Haiyan,WENG Jieyao,QIAN Yilin,et al.Effect of Serum IRGM, Syndecan-1 Level Expression on Prognosis after PCI in Patients with Acute ST-segment Elevation Myocardial Infarction[J].Journal of Modern Laboratory Medicine,2025,40(02):123.[doi:10.3969/j.issn.1671-7414.2025.03.023]
[3]范源洁,张亚云,牛英春.急性心肌梗死患者PCI术前血清lncRNA XIST，miR-140-3p水平与冠状动脉病变程度及预后的相关性研究[J].现代检验医学杂志,2025,40(05):28.[doi:10.3969/j.issn.1671-7414.2025.05.006]
　FAN Yuanjie,ZHANG Yayun,NIU Yingchun.Correlation between Serum lncRNA XIST，miR-140-3p Levels and Degree of Coronary Artery Disease and Prognosis in Patients with Acute Myocardial Infarction before PCI[J].Journal of Modern Laboratory Medicine,2025,40(02):28.[doi:10.3969/j.issn.1671-7414.2025.05.006]

备注/Memo

备注/Memo:
基金项目：秦皇岛市科技计划项目（202301A277）。
作者简介：李天予（1989-），男，大学本科，主治医师，研究方向：心血管相关疾病，E-mail：18633520226@163.com。
更新日期/Last Update: 2025-03-15